Interleukin 1 (IL-1)
receptor-associated kinases (IRAKs) are serine/threonine
kinases that play critical roles in initiating the innate immune response
against foreign pathogens. Additionally, dysregulation of IRAK1 signaling
plays a role in neoplastic disorders. For example, IRAK1 was shown
to be important for survival and proliferation in many B-cell lymphomas,
including Waldenström’s macroglobulinemia (WM) and ABC
subtype Diffused Large B-cell Lymphoma (DLBCL) cells. Here, we report
the discovery of a highly potent and selective covalent inhibitor
of IRAK1, JH-X-119-01. Intact protein MS labeling studies confirmed
that JH-X-119-01 irreversibly labels IRAK1 at C302. This compound
exhibited cytotoxic activity at single digit micromolar concentrations
in a panel of WM, DLBCL, and lymphoma cell lines expressing MYD88.
Cotreatment of JH-X-119-01 with the BTK inhibitor ibrutinib resulted
in synergistic killing effects in these systems. Taken together, JH-X-119-01
represents a highly selective probe of IRAK1 for further development.